Oct 6, 2026 | Press Releases
Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.comKing of Prussia, Pennsylvania–(Newsfile Corp. – October 6, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a...
Oct 5, 2026 | Press Releases
Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania–(Newsfile Corp. – October 5, 2026) – Phio Pharmaceuticals Corp. (NASDAQ:...
Sep 23, 2026 | Press Releases
Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania–(Newsfile Corp. – September 23, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical...
Sep 14, 2026 | Press Releases
Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b TrialKing of Prussia, Pennsylvania–(Newsfile Corp. – September 14, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA...
Sep 11, 2026 | Press Releases
Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762King of Prussia, Pennsylvania–(Newsfile Corp. – September 11, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company...
Aug 11, 2026 | Press Releases
PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.King of Prussia, Pennsylvania–(Newsfile Corp. – August 11, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a...